Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222579 · ClinicalTrials.gov registry record · Phase 2
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
A Phase 2 study of CD19 Positive and Mixed Phenotype Acute Leukemia (MPAL), sponsored by West Virginia University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT07222579 is a Phase 2 study of CD19 Positive and Mixed Phenotype Acute Leukemia (MPAL) that is actively recruiting participants, run by West Virginia University. The registered enrollment target is 78 participants, above the 37-participant average among 4 other CD19 Positive trials with a reported enrollment target (111% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07222579, a Phase 2 study of CD19 Positive and Mixed Phenotype Acute Leukemia (MPAL), is actively recruiting participants, sponsored by West Virginia University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multicenter, non-randomized, open-label, phase II study evaluating blinatumomab administered subcutaneously in adult subjects with CD19+ MPAL. This trial consists of three cohorts of patients with CD19-positive MPAL, categorized as follows: 1. Cohort A: Newly diagnosed CD19+ MPAL in untreated patients who are either ≥ 75 years of age or have at least one coexisting condition precluding intensive chemotherapy. 2. Cohort B: Patients with CD19+ MPAL who have achieved complete remission (CR, CRh, or CRi) following at least one line of treatment but have detectable measurable residual disease (MRD) at a level of ≥ 0.1%, assessed using an assay with a minimum sensitivity of 0.01%. 3. Cohort C: Patients with CD19+ MPAL with morphologic relapsed or refractory (R/R) disease following at least one prior line of treatment. The Primary Objectives for each cohort are for Cohort A: to evaluate the efficacy of SC-blinatumomab in treatment; for Cohort B: to assess the ability of SC-blinatumomab to achieve MRD-negative CR; for Cohort C: to determine the efficacy of SC-blinatumomab in inducing CR, CRh, or CRi in patients. At specified time points, subjects will undergo the following procedures: collection of informed consent, medical history, demographics, ECOG performance, and physical exam including vital signs as well as neurological examination including examination of writing ability. Subjects will provide samples for complete blood count with differential and blood chemistry profile, have a bone marrow aspiration and biopsy and lumbar puncture will be performed per protocol or if clinically indicated, and/or ECG, Echocardiography, pulmonary function test will be performed only if medically indicated. The subcutaneous treatment will be given in both the inpatient and outpatient setting. For an individual subject the length of participation includes up to a 3-week screening period, up to a 13-month treatment period, and a safety follow-up visit (30 days after the last
Conditions Studied
Interventions
- DRUG Subcutaneous Blinatumomab
Study Locations (1)
West Virginia
- West Virginia University Cancer Institute - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2026-02 |
| Est. Completion | 2031-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222579
The ClinicalTrials.gov registry entry for NCT07222579 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 37-participant average among 4 other CD19 Positive trials with a reported enrollment target (111% higher). The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with CD19 Positive appearing as the primary indexed condition, and to 1 intervention - of which Subcutaneous Blinatumomab is the first listed.
NCT07222579 reports 1 study location spanning 1 distinct geographic area - top geographies include West Virginia.
Frequently Asked Questions
What is clinical trial NCT07222579 about?
NCT07222579 is a clinical study titled "Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)". This is a multicenter, non-randomized, open-label, phase II study evaluating blinatumomab administered subcutaneously in adult subjects with CD19+ MPAL. This trial consists of three cohorts of patients with CD19-positive MPAL, categorized as follows: 1. Cohort A: Newly diagnosed CD19+ MPAL in untrea...
What is the current status of trial NCT07222579?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2026-02. Estimated completion is 2031-08.
What conditions does trial NCT07222579 study?
This clinical trial studies the following conditions: CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL).
What interventions are being tested in trial NCT07222579?
The interventions under investigation include: Subcutaneous Blinatumomab (DRUG).
Who is sponsoring clinical trial NCT07222579?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222579 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CD19 Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
CD19 Positive
All registered trials for this condition
Mixed Phenotype Acute Leukemia (MPAL)
All registered trials for this condition
West Virginia
All trials with a study site in West Virginia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.